Q Therapeutics’ Collaborators at Johns Hopkins Are Awarded Funding From NIH

Q Therapeutics is harnessing the power of stem cells to treat debilitating diseases of the central nervous system, which encompass a broad range of diseases including spinal cord injury, transverse myelitis, stroke, ALS, multiple sclerosis, cerebral palsy, Parkinson’s and Alzheimer’s diseases.

Q-Cells® function as ‘mini-factories’ to repair neurons, utilizing multiple pathways including myelination, growth factor production and toxin removal. By utilizing the natural support and repair mechanisms of healthy CNS, safety and efficacy are enhanced. Q has a strong proprietary position with 16 patents issued and 12 pending. Our products address a multi-billion dollar market opportunity for which traditional drugs have failed.
Additional information can be found HERE

Presenter: Deborah Eppstein, Ph.D., President and CEO, Q Therapeutics

Q Therapeutics is an emerging biopharmaceutical company that utilizes cell-based technologies to develop new treatments for debilitating diseases of the central nervous system (CNS). Our company was founded based on the pioneering work of Dr. Mahendra Rao at the University of Utah. In 2004, we began the process of translating decades of research at the University of Utah and the National Institute of Health (NIH) into practical new therapeutic products.

Q’s initial development efforts have focused on natural cell-based products that replace insulating myelin on damaged neurons and produce growth factors and other support for neurons, with the goal of restoring normal neuron function. Our first product, called Q-Cells®, is designed to address a wide range of diseases, including multiple sclerosis (MS), transverse myelitis (TM), ALS (Lou Gehrig’s Disease), cerebral palsy, spinal cord injury, traumatic brain injury, stroke, Parkinson’s Disease and Alzheimer’s Disease. Our patented cellular technologies and manufacturing processes, combined with an experienced management team and a focused strategy, can enable us to develop a comprehensive product pipeline to treat CNS diseases in ways no current drug can.

This entry was posted in Stem Cell Research. Bookmark the permalink.